e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis
Tim Harrison, Giorgio Walter Canonica, Geoffrey Chupp, Jason Lee, Florence Schleich, Tobias Welte, Antonio Valero, Kim Gemzoe, Aoife Maxwell, Sandra Joksaite, Shibing Yang, Peter Howarth, Melissa K. Van Dyke
Source:
Eur Respir J, 56 (4) 2000151; 10.1183/13993003.00151-2020
Journal Issue:
October
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Tim Harrison, Giorgio Walter Canonica, Geoffrey Chupp, Jason Lee, Florence Schleich, Tobias Welte, Antonio Valero, Kim Gemzoe, Aoife Maxwell, Sandra Joksaite, Shibing Yang, Peter Howarth, Melissa K. Van Dyke. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J, 56 (4) 2000151; 10.1183/13993003.00151-2020
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Respiratory sequelae of preterm birth across the life span
Time to breathe: Challenges in the successful management of asthma during conception, pregnancy and delivery
Related content which might interest you:
A single-center observational study assessing response to mepolizumab in severe eosinophilic asthma
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Metabolomic approach in the characterization of omalizumab responders and non-responders among children with severe asthma: a multicenter prospective study.
Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections
Year: 2021
Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: A retrospective observational study
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010
The patterns of inadequate drug administration in children with asthma: a multi-center retrospective study
Source: Eur Respir J 2002; 20: Suppl. 38, 305s
Year: 2002
Real-world effectiveness of omalizumab in allergic asthma patients with low or high blood eosinophils: A retrospective claims analysis study
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018
Omalizumab versus mepolizumab in severe asthma: a propensity score matched efficiency retrospective cohort study
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Real-world exacerbation rates in Japanese patients with COPD: results from the EXACOS observational cohort study
Source: Virtual Congress 2021 – Biomarkers to phenotype COPD: prediction of exacerbations
Year: 2021
Short-term HRQL deterioration during early-phase COPD exacerbation: a prospective Canadian cohort study
Source: Eur Respir J 2005; 26: Suppl. 49, 296s
Year: 2005
Predictor of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study.
Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside
Year: 2017
Efficacy and safety of erdosteine in COPD: Results of a 12-month prospective, multinational study
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Tiotropium discontinuation in patients with early-stage COPD: a prospective observational cohort study
Source: ERJ Open Res, 5 (1) 00175-2018; 10.1183/23120541.00175-2018
Year: 2019
Stop omalizumab: a multicenter follow up study after discontinuation in pediatric patients with severe asthma
Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches
Year: 2021
COPD patients continuing salmeterol or switched to tiotropium: a retrospective analysis of clinical trial data
Source: Eur Respir J 2007; 30: Suppl. 51, 612s
Year: 2007
Real-life effectiveness of omalizumab in difficult-to-treat
versus
severe asthma: a national cohort study in Belgium
Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018
Year: 2019
The evaluation of the efficacy and safety of phospholipids‘ inhalation in patients with bronchial asthma (BA): A prospective randomized placebo-controlled study
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012
Response to benralizumab in severe eosinophilic asthma after intermediate-to-poor response to mepolizumab : a retrospective study.
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020
Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019
A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis
Source: Eur Respir J , 49 (3) 1602486; DOI: 10.1183/13993003.02486-2016
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept